Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.01 (-0.93%)
Close on Nov 11, 2026Market cap $149.51MP/E –Yield –
Compass Therapeutics cash
Cash and short-term investments held at the end of each period.
Compass Therapeutics's cash was $163.06M at Sep 30, 2026. For fiscal 2025 it was $208.91M, up 64.9% from the year before. The highest annual figure on record is $208.91M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.91M | +64.9% |
| FY2024 | Dec 31, 2024 | $126.72M | -16.9% |
| FY2023 | Dec 31, 2023 | $152.46M | -18.3% |
| FY2022 | Dec 31, 2022 | $186.61M | +29.1% |
| FY2021 | Dec 31, 2021 | $144.51M | +207.0% |
| FY2020 | Dec 31, 2020 | $47.08M | +86.0% |
| FY2019 | Dec 31, 2019 | $25.30M | +540677.9% |
| FY2018 | Dec 31, 2018 | $4.68K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $163.06M | -25.8% |
| Q2 FY2026 | Jun 30, 2026 | $179.88M | +78.2% |
| Q1 FY2026 | Mar 31, 2026 | $194.69M | +72.8% |
| Q4 FY2025 | Dec 31, 2025 | $208.91M | +64.9% |
| Q3 FY2025 | Sep 30, 2025 | $219.90M | +86.3% |
| Q2 FY2025 | Jun 30, 2025 | $100.95M | -31.0% |
| Q1 FY2025 | Mar 31, 2025 | $112.64M | -36.0% |
| Q4 FY2024 | Dec 31, 2024 | $126.72M | -16.9% |
| Q3 FY2024 | Sep 30, 2024 | $118.01M | -27.9% |
| Q2 FY2024 | Jun 30, 2024 | $146.23M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $176.06M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | $152.46M | -18.3% |
| Q3 FY2023 | Sep 30, 2023 | $163.70M | +35.7% |
| Q2 FY2023 | Jun 30, 2023 | $168.75M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $175.00M | +28.3% |
| Q4 FY2022 | Dec 31, 2022 | $186.61M | +29.1% |
| Q3 FY2022 | Sep 30, 2022 | $120.60M | +372.8% |
| Q2 FY2022 | Jun 30, 2022 | $132.02M | +323.0% |
| Q1 FY2022 | Mar 31, 2022 | $136.38M | +243.6% |
| Q4 FY2021 | Dec 31, 2021 | $144.51M | +207.0% |
| Q3 FY2021 | Sep 30, 2021 | $25.51M | -54.1% |
| Q2 FY2021 | Jun 30, 2021 | $31.21M | -52.3% |
| Q1 FY2021 | Mar 31, 2021 | $39.70M | +1059846.6% |
| Q4 FY2020 | Dec 31, 2020 | $47.08M | +86.0% |
| Q3 FY2020 | Sep 30, 2020 | $55.52M | +6294457.8% |
| Q2 FY2020 | Jun 30, 2020 | $65.37M | +1343323.8% |
| Q1 FY2020 | Mar 31, 2020 | $3.75K | -20.0% |
| Q4 FY2019 | Dec 31, 2019 | $25.30M | +1034364.4% |
| Q2 FY2019 | Sep 30, 2019 | $882 | -87.8% |
| Q1 FY2019 | Jun 30, 2019 | $4.87K | – |
| Q4 FY2018 | Dec 31, 2018 | $4.68K | – |
| Q2 FY2018 | Sep 30, 2018 | $2.45K | – |
| Q1 FY2018 | Jun 30, 2018 | $7.23K | – |
See a number that looks wrong?